The company said Sunday it had received a complete response letter from the Food and Drug Administration concerning its biologics license application. The application sought approval for ivonescimab combined with platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had already received certain therapies.
Summit shares had lost about a fifth of their value year to date through Friday’s close. Robert Duggan, the company’s co-chief executive, said Summit was “disappointed for patients and their families awaiting additional treatment options in this setting.”
Ivonescimab was initially approved for marketing authorization in China in May 2024. It was developed there by Summit’s partner Akeso. The treatment has not been approved by any regulatory authority in Summit’s license territories, including the U.S. and Europe.




Comments (0)
No comments yet. Be the first!